➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,915,275

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,915,275 protect, and when does it expire?

Patent 7,915,275 protects XIFAXAN and is included in one NDA.

This patent has ninety-four patent family members in thirty-seven countries.

Summary for Patent: 7,915,275
Title:Use of polymorphic forms of rifaximin for medical preparations
Abstract: The present invention relates to Rifaximin polymorphic forms .alpha., .beta. and .gamma., to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.
Inventor(s): Viscomi; Giuseppe C. (Bologna, IT), Campana; Manuela (Bologna, IT), Confortini; Donatella (Bologna, IT), Barbanti; Miriam (Bologna, IT), Calanni; Fiorella (Bologna, IT)
Assignee: Alfa Wassermann, S.p.A. (Bologna, IT)
Application Number:11/873,841
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,915,275
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Formulation;

Drugs Protected by US Patent 7,915,275

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF. ⤷  Try it Free
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS. ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,915,275

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI03A2144Nov 7, 2003

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.